Serov Holdings

Serov is a clinical-stage biotechnology company focused on the discovery and development of microbiome-derived therapeutics for inflammatory and metabolic diseases. The company was established in 2023 following the acquisition of the therapeutic assets and the SG-Microbiome discovery platform from Second Genome. Serov utilizes its proprietary platform to identify specific microbial-derived proteins and small molecules that play critical roles in human health and disease. Its lead clinical candidate, SG-2-0776, is a small molecule MALT1 inhibitor being evaluated for the treatment of Inflammatory Bowel Disease (IBD). By integrating microbiome science with drug discovery, Serov aims to deliver precision medicines that address significant unmet needs in immunology and metabolic health. The company is led by an experienced management team with deep expertise in microbiome research and drug development.